Skip to content


  • Research article
  • Open Access
  • Open Peer Review

CHI3L1polymorphisms associate with asthma in a Taiwanese population

  • 1,
  • 2, 3,
  • 4,
  • 5,
  • 5,
  • 5,
  • 1,
  • 1,
  • 1 and
  • 1Email author
BMC Medical Genetics201415:86

  • Received: 11 March 2014
  • Accepted: 8 July 2014
  • Published:
Open Peer Review reports



A genome-wide association study uncovered Chitinase 3 like 1 (CHI3L1) as a candidate gene for asthma susceptibility. CHI3L1, which encodes the YKL-40 protein, is associated with asthma in Western European and American populations and with atopy in a Korean population. However, asthma-associated polymorphisms remain unknown for a Taiwanese population.


We enrolled 628 adult asthmatic patients and 1:1 age-sex matched community-based controls in southern Taiwan and performed a combined effect sizes analysis to test if CHI3L1 polymorphisms were related to genetic risks for asthma in the Asian population. Ten tagSNP polymorphisms for the CHI3L1 gene were selected from the HapMap database and genotyped using a TaqMan allelic discrimination assay.


Adjusted odds ratios of the CHI3L1 rs1538372 CC genotype (aOR = 1.97, 95% CI: 1.23–3.14) and the rs10399931 GG genotype (aOR = 1.77, 95% CI: 1.13–2.77) were significantly associated with asthma in the Taiwanese populations. Predictive values of forced expiratory volume in the first second of the forced vital capacity (12.37%, P = 0.03) and of forced vital capacity (12.10%, P = 0.036) decreased in conjunction with an increase in YKL-40 levels among CHI3L1 rs1538372 CC carriers; these values were 16.1% (P = 0.004) and 14.5% (P = 0.011), respectively, among CHI3L1 rs10399931 GG carriers. Furthermore, steroid use by asthma patients did not affect serum YKL-40 levels, but both polymorphisms had significant effects on YKL-40 levels in asthma patients who used steroids.


Our findings suggest that the CHI3L1 polymorphisms rs1538372 and rs10399931 can be used as genetic markers for predicting asthma risk in the Taiwanese population.


  • Asthma severity
  • CHI3L1
  • Lung function
  • Polymorphism
  • YKL-40


Asthma has a complicated etiology, including airway inflammation, bronchial hyper-responsiveness, and a variable degree of airway obstruction that is influenced by environmental [1] and genetic factors [2]. This disease impacts more than 300 million people worldwide and has detrimental effects on the quality of life [3].

Chitin is a widely abundant polysaccharide in nature, which triggers allergies or asthma attacks in people. It is found in fungi, as well as many arthropods, including cockroaches, house dust mites, and seafood crustaceans (such as shrimp, prawn, and crab). The mammalian 18 glycosyl hydrolase family has three members, two of which are chitinase chitotriosidase (CHIT1) and acidic mammalian chitinase (AMCase), with evolutionarily conserved glycosyl hydrolase activities that cleave chitin and consequently regulate the innate immune response [4].

The third 18 glycosyl hydrolase family member, YKL-40, is encoded by the chitinase 3-like 1 (CHI3L1) gene located on chromosome 1q32.1 (also called human cartilage gp-39/HcGp-39 or breast regression protein 39/BRP-39) [5, 6]. YKL-40 has chitin-binding activity but lacks chitinase activity and is produced by the airway epithelium, alveolar macrophages, lung fibroblasts, chondrocytes, synovial cells, breast cells, and hepatic cells. In addition, YKL-40 plays critical roles in inflammation, tissue remodeling, and fibrosis during infection, joint disease, liver fibrosis, and cancer [7]. Additionally, novel functions of YKL-40 are mediated by the Th2-inflammation pathway, which was fully demonstrated in BRP-39 gene knockout mice and YKL-40 transgenic mice [8].

Previous cohort studies have shown that elevated levels of serum YKL-40 are significantly associated with asthmatic severity and poor lung function, because the thickness of the bronchial subepithelial basement membrane is positively correlated with YKL-40 levels [9]. A genome-wide association study of asthma indicated that the single nucleotide polymorphism (SNP) rs4950928 in the promoter region of CHI3L1 is associated with serum levels of YKL-40 in Western European and American populations [10, 11], and another study illustrated that the rs4950928 G allele is significantly associated with asthma susceptibility in a population-based study of 6514 Danish adults [12]. Moreover, rs10399805 and rs2275353 in CHI3L1 were found be significantly associated with atopy but not asthma in a Korean population [13].

Although another study in sixty-two asthmatic patients found YKL-40 levels correlated with exacerbation of attacks [14], whether inherent and susceptible genetic variance of CHI3L1 affects the serum YKL-40 protein levels that cause asthmatic severity in a Taiwanese population is not known. Therefore, we selected 10 tagSNPs of the CHI3L1 gene using Tagger pairwise methods, explored the association between the CHI3L1 gene and asthma risk, and measured decreased lung function with forced expiratory volume in the first second of the forced vital capacity (FEV1) and forced vital capacity (FVC), which are regarded as indicators of asthmatic symptom severity.


Study population

We enrolled adult asthmatic patients and 1:1 age-sex matched community-based controls in southern Taiwan. The asthmatic patients were diagnosed at Kaohsiung Chang Gung Memorial Hospital (CGMH) and Kaohsiung Medical University Hospital (KMUH). The 628 adult asthmatic patients had symptoms such as cough, wheezing, episodic breathlessness, and chest tightness according to the Global Initiative for Asthma guidelines and/or an increase in FEV1 of ≥12% and at least 200 mL from the prebronchodilator value based on lung function testing [15]. The 628 healthy control subjects were recruited at local health stations in the same geographic communities as our previous description [16]. In the study, all subjects with symptoms indicating lung cancer, tuberculosis, bronchitis, or pneumonia were excluded.

All participants provided informed written consent, which was reviewed and approved by the Institutional Review Boards of CGMH and KMUH (ethics approval numbers, CGMH-101-0614C and KMUH-IRB-980553).

Ascertainment of relevant metrics

Blood samples were collected from all participants who completed a questionnaire that collected comprehensive information regarding demographics, smoking habits, parents’ asthmatic history, history of atopic disease diagnosed by a physician, steroid use (including oral or inhaled steroids), and environmental exposure factors. Spirometry was performed according to the American Thoracic Society standards [17], and FEV1and FVC were measured. All recorded data were measured three times, and the highest score was recorded under stable conditions. Total blood serum immunoglobulin E (IgE) and YKL-40 protein levels were measured using a microparticle enzyme immunoassay (IMX system Abbot, Tokyo, Japan) and the DuoSet® ELISA Development System (R&D Systems, Inc., Minneapolis, MN, USA), respectively.

TagSNP selection and genotyping

The CHI3L1 tagSNPs (rs903358, rs7542294, rs946259, rs880633, rs12128727, rs1538372, rs10399805, rs10399931, rs6691378, and rs946261) were selected by using the Tagger pairwise and linkage disequilibrium (LD) measurement methods on the HapMap2009 NCBI B36 assembly Chinese Han (CHB) database with minor allele frequency (MAF) ≥0.05 and r 2 ≥ 0.80. Linkage disequilibrium blocks of the CHI3L1 gene region extending from 201,413 kb to 201,430 kb on chromosome 1 were established in Haploview version 4.2 ( (Figure S1 in the online Additional file 1). Overall, the characteristics of the 10 tagSNPs are described in Table S1 in the online Additional file 2. Genomic DNA was isolated from peripheral blood using the Purgene DNA Isolation Kit (Gentra Systems, Inc., Minneapolis, MN, USA). Genotyping was performed with the TaqMan® SNP Genotyping Assay standard protocol with a 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Duplicate genotyping of 10% of the samples (selected randomly) was performed for quality control.

Statistical analysis

All analyses were performed using IBM SPSS Statistics release 19.0 (SPSS Inc., an IBM Company, Chicago, IL, USA). Comparisons of the asthmatic and control subjects were conducted using Pearson’s chi-squared test for the dichotomous variables and the t test for the continuous variables. Serum IgE and YKL-40 levels did not show a normal distribution on the Shapiro–Wilk test (P < 0.001) and needed to be log-transformed for normality. We performed using the Pearson’s chi-squared test to assess Hardy–Weinberg equilibrium for allele distribution in the asthmatic and control groups. Adjusted odds ratios (aORs) with 95% confidence intervals (CI) according to carriers of recessive, dominant, and co-dominant genotypes were assessed with logistic regression analysis adjusting for sex, age, body mass index (BMI), log IgE, smoking, exposure to pets, indoor incense burning, and parental asthma history. To examine the effects of CHI3L1 genotype on quantitative clinical characteristics in asthmatic patients and controls groups, we performed ANOVA with a Bonferroni adjustment (post hoc comparison) and multiple linear regressions adjusting for age, sex, log IgE, BMI, and smoking as covariates.


Characteristics of patients

Between the 628 asthmatic patients and 628 healthy controls, there were significant differences in body weight, BMI, waist circumference, hip circumference, waist-to-hip ratio, serum IgE and YKL-40 levels, lung function, smoking and drinking behavior, exposure to indoor pets and incense burning, and parents’ asthma history (Table 1).
Table 1

The demographic characteristics of asthmatics and controls


Asthma Na = 628

Control Na = 628

P valued

Age (years)b

51.44 ± 14.13

50.42 ± 11.84





289 (46.0%)

289 (46.0%)



339 (54.0%)

339 (54.0%)


Height (cm)b

162.15 ± 8.33

161.82 ± 8.28


Weight (kg)b

66.56 ± 12.47

63.04 ± 11.86


BMI (kg/m2)ab

25.27 ± 4.07

23.95 ± 3.40


WC (cm)ab

86.93 ± 11.18

78.58 ± 9.51


Hips (cm)b

99.33 ± 8.88

95.74 ± 6.62



0.88 ± 0.08

0.82 ± 0.08


IgE (IU/mL)b

262.04 ± 584.65

128.07 ± 291.48


YKL-40 (ng/mL)b

112.84 ± 111.56

95.65 ± 101.46


Lung functionb


FEV1%, pred

81.75 ± 21.53

92.17 ± 16.41


FVC%, pred

85.75 ± 21.31

97.36 ± 17.05


FEV1/FVC ratio

0.96 ± 0.15

0.95 ± 0.12





69 (11.1%)

82 (13.1%)



99 (15.9%)

44 (7.0%)



456 (73.1%)

502 (79.9%)


Drinking habits



72 (11.5%)

60 (9.7%)



38 (6.1%)

18 (2.9%)



515 (82.4%)

541 (87.4%)


Indoor environmental factors


Pets (dogs, cats, birds)

190 (30.4%)

103 (21.5%)


Appearance of cockroaches

491 (%)



Air cleaner

102 (16.3%)

66 (13.8%)



140 (22.5%)




26 (4.2%)

18 (3.8%)


Mold in walls




Indoor incense burning

402 (64.5%)

215 (45.2%)


Asthma history for father, yes

69 (11.2%)

23 (4.6%)


Asthma history for mother, yes

51 (8.2%)

17 (3.4%)


a Abbreviations: BMI body mass index, WC waist circumference, WHR waist-to-hips ratio, N number of individuals.

bValues are expressed as the means ± standard deviation (SD) unless otherwise stated.

cThe P value of the IgE and YKL-40 serum levels was determined by t test after log-transformation.

dThe P value was calculated for the continuous variables by the t test, and the χ2 test was used for the categorical variable.

CHI3L1tagSNP association study

For the association analysis, we identified 10 tagSNPs for CHI3L1 from the HapMap 2009 NCBI B36 assembly of the Chinese Han database (Table S1 in Additional file 2). The association results are presented in Table S2 in Additional file 3. CHI3L1 genotypes and allele carrier frequencies were calculated in the asthmatic patients and controls.

No deviation from Hardy–Weinberg equilibrium was observed for the 10 tagSNPs. Only rs1538372 (P = 0.014) and rs10399931 (P = 0.047) had a nominally significant association with asthma, respectively. However, the two polymorphisms rs1538372 (P = 0.14) and rs10399931 (P = 0.47) and other eight genotypes were not significantly associated with asthma after applying the Bonferroni correction.

Furthermore, we observed that for the aOR in rs1538372, the CC genotype was associated with an increased risk of asthma compared with the TT genotype (aOR = 1.97, 95% CI 1.23–3.14). For rs10399931, the GG genotype was associated with an increased risk of asthma compared with the AA genotype (aOR = 1.77, 95% CI 1.13–2.77) (Table 2).
Table 2

The adjusted odd ratios between asthma status and the CHI3L1 polymorphisms rs1538372 and rs10399931 according to three inheritance modes



OR (95% CI)

aOR (95% CI)a



  Co-dominant genotype








1.3 (0.91–1.86)

1.54 (0.98–2.43)



1.65 (1.15–2.38)

1.97 (1.23–3.14)

  Recessive genotype


   TT + TC






1.34 (1.07–1.68)

1.39 (1.04–1.86)

  Dominant genotype






   TC + CC


1.45 (1.03–2.04)

1.72 (1.11–2.66)



  Co-dominant genotype








1.16 (0.82–1.65)

1.36 (0.88–2.10)



1.47 (1.03–2.11)

1.77 (1.13–2.77)

  Recessive genotype


   AA + GA






1.31 (1.04–1.64)

1.39 (1.04–1.86)

Dominant genotype






   GA + GG


1.30 (0.93–1.81)

1.53 (1.01–2.32)

aAdjusted odds ratio and 95% confidence intervals (aOR and 95% CI) are shown using multiple logistic regressions to control variables, including sex, age, BMI, logIgE, smoking, pet exposure, indoor incense burning, and parents’ asthma history.

Association of clinical quantitative characteristics

We investigated the differences in clinical quantitative traits, including adiposity, serum levels of IgE and YKL-40, and lung function, among subjects with CHI3L1 rs1538372 and rs10399931 genotypes in asthmatic patients and control groups. A significant association was revealed between the rs1538372 and rs10399931 genotypes and serum YKL-40 protein levels (Table 3). In this study, we found that FEV1% and FVC% decreased by 12.37% (P = 0.03) and 12.10% (P = 0.036), respectively, as YKL-40 levels were higher in CHI3L1 rs1538372 CC carriers than in TC or TT carriers. Similarly, FEV1% and FVC% in subjects with CHI3L1 rs10399931 GG genotype were significantly lower at -16.1% (P = 0.004) and -14.5% (P = 0.011), respectively (Table 4).
Table 3

The associations of the CHI3L1 rs1538372 and rs10399931 polymorphisms with clinical status and characteristics in asthma and control groups





CC (N = 270)

CT (N = 293)

TT (N = 65)

P value

CC (N = 226)

CT (N = 311)

TT (N = 91)

P value

Age (year)

51.40 ± 14.26

51.14 ± 14.08

52.91 ± 13.91


50.00 ± 11.86

50.78 ± 11.64

50.22 ± 12.58





120 (44.4%)

142 (48.5%)

27 (41.5%)


108 (47.8%)

141 (45.3%)

40 (44.0%)



150 (55.6%)


38 (58.5%)


118 (52.2%)

170 (54.7%)

51 (56.0%)


BMI (kg/m2)

25.31 ± 4.25

25.3 ± 3.93

25.00 ± 3.92


23.85 ± 3.54

23.88 ± 3.31

24.47 ± 3.36


WC (cm)

86.70 ± 12.00

87.18 ± 10.83

86.74 ± 8.89


79.21 ± 10.20

77.67 ± 9.03

80.06 ± 9.02



0.88 ± 0.09

0.88 ± 0.08

0.87 ± 0.06


0.83 ± 0.10

0.81 ± 0.07

0.82 ± 0.07


IgE (IU/mL)

279.24 ± 648.79

221.09 ± 399.22

375.48 ± 913.44


111.64 ± 190.17

137.02 ± 337.76

140.32 ± 336.82


YKL-40 (ng/mL)

130.00 ± 126.89

103.79 ± 101.13

81.18 ± 69.18

< 0.0001a

115.47 ± 128.54

88.441 ± 84.23

68.32 ± 61.35


FEV1%, pred

84.00 ± 20.66

79.71 ± 21.73

79.26 ± 23.42


91.91 ± 17.46

93.36 ± 15.64

88.75 ± 15.88


FVC%, pred

87.47 ± 21.03

84.32 ± 20.40

84.94 ± 25.67


97.08 ± 16.90

97.52 ± 17.78

97.54 ± 15.01



GG (N = 270)

GA (N = 286)

AA (N = 72)

P value

GG (N = 229)

GA (N = 307)

AA (N = 90)

P value

Age (year)

51.28 ± 14.14

51.16 ± 14.06

53.13 ± 14.41


50.32 ± 11.63

50.32 ± 11.79

50.97 ± 12.72





122 (45.2%)

136 (47.6%)

31 (43.1%)


112 (48.9%)

136 (44.3%)

40 (44.4%)



148 (54.8%)

150 (52.4%)

41 (56.9%)


117 (51.1%)

171 (55.7%)

50 (55.6%)


BMI (kg/m2)

25.24 ± 4.29

25.36 ± 3.87

25.06 ± 4.04


23.82 ± 3.33

23.96 ± 3.46

24.16 ± 3.34


WC (cm)

86.54 ± 11.91

87.08 ± 10.87

87.78 ± 9.47


78.84 ± 9.71

78.08 ± 9.50

79.40 ± 9.01



0.87 ± 0.09

0.88 ± 0.08

0.88 ± 0.07


0.83 ± 0.10

0.82 ± 0.07

0.82 ± 0.07


IgE (IU/mL)

276.80 ± 645.41

229.82 ± 454.97

331.63 ± 768.03


95.65 ± 155.72

150.11 ± 346.92

139.44 ± 351.86


YKL-40 (ng/mL)

133.08 ± 128.56

99.16 ± 89.75

90.66 ± 109.85

< 0.0001a

105.15 ± 103.82

98.89 ± 108.91

63.403 ± 57.64


FEV1%, pred

83.20 ± 20.89

80.96 ± 22.16

77.41 ± 21.05


92.81 ± 18.37

92.91 ± 14.58

88.30 ± 16.71


FVC%, pred

86.79 ± 20.83

85.09 ± 21.67

84.44 ± 21.79


98.69 ± 18.26

96.42 ± 16.31

97.18 ± 16.48


a P value was presented by testing the total serum IgE and YKL-40 levels after log-transformation to follow normal distribution. (ANOVA and Bonferroni).

Table 4

The correlations between serum YKL-40 levels and lung functions according to the CHI3L1 polymorphisms in asthmatics


Lung function FEV1% predicted

Lung function FVC% predicted

Serum YKL40 level (log-transformation)

β ± SE

r coefficient

P valuea

β ± SE

r coefficient





-3.61 ± 11.768



0.379 ± 13.74




-11.38 ± 5.20



-12.95 ± 5.01




-12.37 ± 5.526



-12.10 ± 5.71






-12.11 ± 8.644



-11.60 ± 9.95




-6.90 ± 5.83



-8.98 ± 5.74




-16.10 ± 5.50



-14.5 ± 5.70



aLinear regression was performed adjusting for age, sex, logIgE, BMI, and smoking.

Further, using CHI3L1 polymorphisms, we determined whether steroid use affected serum YKL-40 levels in asthmatics. We found no significant difference in serum YKL-40 levels between asthmatic subjects who did and did not use steroids (Figure 1A). However, it is noteworthy that YKL-40 levels varied by rs1538372 genotypes (CC > TC > TT, P for trend = 0.001) and rs10399931 (GG > GA > AA, p for trend = 0.001) in asthmatic patients who used steroids (Figure 1B).
Figure 1
Figure 1

The YKL-40 levels were affected by rs1538372 and rs10399931 genotypes in asthmatics. (A) The serum YKL-40 levels were assessed in asthmatics using steroids or not using steroids. Mean ± standard error (SE) is shown with significance assessed by t test. (B) The serum YKL-40 levels were analyzed according to rs1538372 and rs10399931 genotypes in asthmatics using steroids or not using steroids. Mean ± standard error (SE) is shown. The mean trend tests were performed by entering cross-categorized variables as a continuous variable into the linear regression model and including multiple testing corrections (Bonferroni; P* < 0.05).


Following the discovery that CHI3L1 variation affects serum YKL-40 levels, the risk of asthma and impaired lung function were studied in Western European and American populations with a genome-wide association method [10]. In fact, we are the first to demonstrate that the CHI3L1 polymorphisms rs1538372 and rs10399931 in the Taiwanese population were not only significantly associated with asthma risk, but also related to serum YKL-40 concentrations with a gene-dose dependent relationship. At the same time, we found that the percent predictive value of FEV1 and FVC among CHI3L1 rs1538372 CC carriers was lower than in TC or TT carriers, and similar findings were observed for rs10399931 GG carriers compared to GA or AA carriers.

In a Korean population study (198 asthmatics and 277 non-asthmatics), the C versus T allele of the rs1538372 polymorphism and the G versus A allele of rs10399931 polymorphism were associated with an increased risk of asthma (OR = 1.26 and 1.19, respectively) [13]. However, the differences were not statistically significant; therefore, it was concluded that the two polymorphisms did not increase asthma risk. Interestingly, our matched data set (628 asthmatics and 628 controls) gave significant odds ratios for the rs1538372 C allele (OR = 1.27, 95% CI: 1.08-1.49) and the rs10399931 G allele (OR = 1.22, 95% CI: 1.04-1.44) associations with asthma. The differences between the studies are due to the different sample sizes. Overall, the two SNPs were consistently associated with increased asthma risk and could be considered important risk markers for asthma in Asians.

Verlann and coworkers [18] constructed luciferase-based reporter vectors including three variant genotypes: the rs10399931 C allele (complementary to the G risk allele on the reverse strand), the rs10399805 A allele, and the rs4950928 C allele. Their study found that the haplotype CAC (or GTG haplotype) has the highest promoter activity compared with the other haplotypes. They concluded that rs103999331 and rs4950925 are equally likely to modulate CHI3L1 expression and susceptibility to asthma in Caucasian and African populations.

To treat asthmatic patients in the clinical setting, inhaled or oral glucocorticoids are commonly administered, owing to their direct inhibitory effects on airway inflammation [19]. Glucocorticoid is a type of steroid hormone that binds to the glucocorticoid receptor to translocate into the nucleus, where it binds to specific DNA elements to regulate gene expression [20]. We found that the transcription factor–binding sites of glucocorticoid receptor element (GRE) and STAT1 are closer to rs1538372 and that cAMP response element–binding protein (CREBP1) and E4 promoter–binding protein 4 (E4BP4) are closer to rs10399931 from UCSC Genome Browser (NCBI36/hg18) [21, 22] (Figure S2 in the online Additional file 4 and Table S3 in the online Additional file 5). There is convincing evidence for STAT1 constitutive activation in the asthmatic airway epithelium [23]. The E4BP4 protein, which binds to elements located on the promoters of the repressed COX-2 and iNOS genes, was induced by glucocorticoid dexamethasone [24]. Thus, the two SNPs in the CHI3L1 gene might be affected by glucocorticoids.

Here, we first found that serum YLK-40 levels were not different between asthmatic patients who did or did not use steroids. Furthermore, serum YKL-40 levels were highly elevated by dependent genotypes in steroid-using asthma patients with rs1538372 CC and rs10399931 GG. These results showed that the rs1538372 CC and rs10399931 GG are risk genotypes associated with severity of asthmatic lung function. The steroid-using asthmatic subjects who have genotypes rs1538372 CC and rs10399931 GG will be examined in a future study to clarify whether these risk carriers might be associated with steroid resistance.

Here, we summarized the mechanisms of regulation of CHI3L1 gene expression on bronchial epithelium, smooth muscle, monocytes, and macrophages to elucidate the role of the CHI3L1 gene in asthmatic pathology. We factored in numerous environmental factors, such as smoking, house dust mite exposure [25], rhinovirus [26], lipopolysaccharide infection [27], and interleukin 13 [8]. It is well known that the AKT-MAPK-ATF2 or STAT1 signaling pathways are implicated in YKL-40 expression or exacerbation of asthma symptoms (Figure S3 in the online Additional file 6).

Overall, the limitations of the study need to be discussed. We found that the CHI3L1 polymorphisms rs1538372 and rs10399931 had an r 2 of 0.84 in a linkage disequilibrium plot (Additional file 2: Table S1) and a nominally significant association with asthma (P < 0.05). The correlations were not significant after Bonferroni correction. However, two SNPs were significantly associated with asthma and significantly associated with serum YKL-40 levels and lung functions in asthmatic according to multiple regression models after adjusting for potential confounding factors. Importantly, we managed to reduce false positive results and avoid excluding small effects through the overly conservative Bonferroni correction. Furthermore, there are still limitations that require further large-scale exploration to clarify gene-gene and gene-environment interactions.

Taken together, protein YKL-40 levels are elevated in many kinds of diseases, such as asthma, multiple sclerosis, rheumatoid arthritis, osteoarthritis, infectious diseases, cardiovascular disease, and cancer. Thus, serum YKL-40 levels are not a specific diagnosis for one disease, and now several studies question whether unregulated YKL-40 is a good diagnostic biomarker in many diseases. YKL-40 may not be a good biomarker, but it can reflect poor prognosis [7] and overall mortality risk [28].


Our findings suggest that CHI3L1 polymorphisms rs1538372 and rs10399931 can be used as genetic markers predicting asthma risk in the Taiwanese population.



This work was supported by grants from the National Science Council in Taiwan [99-2314-B-037-056-MY2, NSC100-2314-B-037-025-MY3, and MOST 103-2314-B-037-018-MY3].

Authors’ Affiliations

Department of Public Health, College of Health Science, Kaohsiung Medical University, No. 100, Shi-Chuan 1st Rd, Kaohsiung, 807, Taiwan
Environment-Omics-Diseases Research Center, China Medical University Hospital, Taichung, Taiwan
Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan
Division of Pulmonary and Critical care Medicine and Geriatric Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
Division of Pulmonary and Critical Care Medicine, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan


  1. Maddox L, Schwartz DA: The pathophysiology of asthma. Annu Rev Med. 2002, 53: 477-498.View ArticlePubMedGoogle Scholar
  2. Wills-Karp M, Ewart SL: Time to draw breath: asthma-susceptibility genes are identified. Nat Rev Genet. 2004, 5 (5): 376-387.View ArticlePubMedGoogle Scholar
  3. Siroux V, Boudier A, Anto JM, Cazzoletti L, Accordini S, Alonso J, Cerveri I, Corsico A, Gulsvik A, Jarvis D, de Marco R, Marcon A, Marques EA, Bugiani M, Janson C, Leynaert B, Pin I: Quality-of-life and asthma-severity in general population asthmatics: results of the ECRHS II study. Allergy. 2008, 63 (5): 547-554.View ArticlePubMedGoogle Scholar
  4. Lee CG, Da Silva CA, Lee JY, Hartl D, Elias JA: Chitin regulation of immune responses: an old molecule with new roles. Curr Opin Immunol. 2008, 20 (6): 684-689.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Hakala BE, White C, Recklies AD: Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem. 1993, 268 (34): 25803-25810.PubMedGoogle Scholar
  6. Rehli M, Krause SW, Andreesen R: Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics. 1997, 43 (2): 221-225.View ArticlePubMedGoogle Scholar
  7. Johansen JS: Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006, 53 (2): 172-209.PubMedGoogle Scholar
  8. Lee CG, Hartl D, Lee GR, Koller B, Matsuura H, Da Silva CA, Sohn MH, Cohn L, Homer RJ, Kozhich AA, Humbles A, Kearley J, Coyle A, Chupp G, Reed J, Flavell RA, Elias JA: Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med. 2009, 206 (5): 1149-1166.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Chupp GL, Lee CG, Jarjour N, Shim YM, Holm CT, He S, Dziura JD, Reed J, Coyle AJ, Kiener P, Cullen M, Grandsaigne M, Dombret MC, Aubier M, Pretolani M, Elias JA: A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med. 2007, 357 (20): 2016-2027.View ArticlePubMedGoogle Scholar
  10. Ober C, Tan Z, Sun Y, Possick JD, Pan L, Nicolae R, Radford S, Parry RR, Heinzmann A, Deichmann KA, Lester LA, Gern JE, Lemanske RF, Nicolae DL, Elias JA, Chupp GL: Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med. 2008, 358 (16): 1682-1691.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Ober C, Chupp GL: The chitinase and chitinase-like proteins: a review of genetic and functional studies in asthma and immune-mediated diseases. Curr Opin Allergy Clin Immunol. 2009, 9 (5): 401-408.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Rathcke CN, Holmkvist J, Husmoen LL, Hansen T, Pedersen O, Vestergaard H, Linneberg A: Association of polymorphisms of the CHI3L1 gene with asthma and atopy: a populations-based study of 6514 Danish adults. PLoS One. 2009, 4 (7): e6106-View ArticlePubMedPubMed CentralGoogle Scholar
  13. Sohn MH, Lee JH, Kim KW, Kim SW, Lee SH, Kim KE, Kim KH, Lee CG, Elias JA, Lee MG: Genetic variation in the promoter region of chitinase 3-like 1 is associated with atopy. Am J Respir Crit Care Med. 2009, 179 (6): 449-456.View ArticlePubMedGoogle Scholar
  14. Tang H, Fang Z, Sun Y, Li B, Shi Z, Chen J, Zhang T, Xiu Q: YKL-40 in asthmatic patients, and its correlations with exacerbation, eosinophils and immunoglobulin E. Eur Respir J. 2010, 35 (4): 757-760.View ArticlePubMedGoogle Scholar
  15. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, Gibson P, Ohta K, O'Byrne P, Pedersen SE, Pizzichini E, Sullivan SD, Wenzel SE, Zar HJ: Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008, 31 (1): 143-178.View ArticlePubMedGoogle Scholar
  16. Wang TN, Lin MC, Wu CC, Leung SY, Huang MS, Chuang HY, Lee CH, Wu DC, Ho PS, Ko AM, Chang PY, Ko YC: Risks of exposure to occupational asthmogens in atopic and nonatopic asthma: a case–control study in Taiwan. Am J Respir Crit Care Med. 2010, 182 (11): 1369-1376.View ArticlePubMedGoogle Scholar
  17. Society AT: Standardization of spirometry–1987 update. Statement of the American Thoracic Society. Am Rev Respir Dis. 1987, 136 (5): 1285-1298.View ArticleGoogle Scholar
  18. Verlaan DJ, Ouimet M, Adoue V, Sirois-Gagnon D, Lariviere M, Ge B, Beaulieu P, Dias J, Lam KC, Koka V, Laprise C, Pastinen T, Sinnett D: Promoter polymorphisms in CHI3L1 are associated with asthma. J Allergy Clin Immunol. 2012, 130 (2): 533-535.View ArticlePubMedGoogle Scholar
  19. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ: Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med. 1997, 155 (2): 542-548.View ArticlePubMedGoogle Scholar
  20. Adcock IM, Caramori G: Cross-talk between pro-inflammatory transcription factors and glucocorticoids. Immunol Cell Biol. 2001, 79 (4): 376-384.View ArticlePubMedGoogle Scholar
  21. Neph S, Vierstra J, Stergachis AB, Reynolds AP, Haugen E, Vernot B, Thurman RE, John S, Sandstrom R, Johnson AK, Maurano MT, Humbert R, Rynes E, Wang H, Vong S, Lee K, Bates D, Diegel M, Roach V, Dunn D, Neri J, Schafer A, Hansen RS, Kutyavin T, Giste E, Weaver M, Canfield T, Sabo P, Zhang M, Balasundaram G, et al: An expansive human regulatory lexicon encoded in transcription factor footprints. Nature. 2012, 489 (7414): 83-90.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Sanyal A, Lajoie BR, Jain G, Dekker J: The long-range interaction landscape of gene promoters. Nature. 2012, 489 (7414): 109-113.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Sampath D, Castro M, Look DC, Holtzman MJ: Constitutive activation of an epithelial signal transducer and activator of transcription (STAT) pathway in asthma. J Clin Invest. 1999, 103 (9): 1353-1361.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Wallace AD, Wheeler TT, Young DA: Inducibility of E4BP4 suggests a novel mechanism of negative gene regulation by glucocorticoids. Biochem Biophys Res Commun. 1997, 232 (2): 403-406.View ArticlePubMedGoogle Scholar
  25. Nikota JK, Botelho FM, Bauer CM, Jordana M, Coyle AJ, Humbles AA, Stampfli MR: Differential expression and function of breast regression protein 39 (BRP-39) in murine models of subacute cigarette smoke exposure and allergic airway inflammation. Respir Res. 2011, 12: 39-View ArticlePubMedPubMed CentralGoogle Scholar
  26. Hall DJ, Bates ME, Guar L, Cronan M, Korpi N, Bertics PJ: The role of p38 MAPK in rhinovirus-induced monocyte chemoattractant protein-1 production by monocytic-lineage cells. J Immunol. 2005, 174 (12): 8056-8063.View ArticlePubMedGoogle Scholar
  27. Di Rosa M, Malaguarnera G, De Gregorio C, Drago F, Malaguarnera L: Evaluation of CHI3L-1 and CHIT-1 expression in differentiated and polarized macrophages. Inflammation. 2013, 36 (2): 482-492.View ArticlePubMedGoogle Scholar
  28. Mygind ND, Iversen K, Kober L, Goetze JP, Nielsen H, Boesgaard S, Bay M, Johansen JS, Nielsen OW, Kirk V, Kastrup J: The inflammatory biomarker YKL-40 at admission is a strong predictor of overall mortality. J Intern Med. 2013, 273 (2): 205-216.View ArticlePubMedGoogle Scholar
  29. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:


© Tsai et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.